Rituximab-induced interstitial lung disease

American Journal of Hematology

Volumn 82, Issue 10, 2007, Pages 916-919

  Wagner, Stephanie A ^a   Mehta, Apurva C ^a   Laber, Damian A ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; B CELL LYMPHOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC IMAGING; DRUG EFFECT; DYSPNEA; FEVER; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERSTITIAL LUNG DISEASE; LARGE CELL LYMPHOMA; LUNG BIOPSY; LUNG FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SYMPTOM;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COUGH; CYCLOPHOSPHAMIDE; DOXORUBICIN; DYSPNEA; FATAL OUTCOME; FEVER; HUMANS; LUNG DISEASES, INTERSTITIAL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

EID: 34848909646     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20910     Document Type: Review

References (17)

1. Rastetter W, Molina A, White CA. Rituximab: Expanding role in the therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503.
2. Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor α release is a major biological event associated with rituximab therapy. Hematol J 2001;2:378-384.
3. Genentech Report, Rituxan and Pulmonary Events, 2005.
4. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant b-cell lymphocytosis. Leuk Lymphoma 2001;42:1329-1337.
5. Hainsworth JD, Litchy S, Lamb MR, Rodriquez GL, Scroggin C, Greco A. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate grade non-Hodgkin's lymphoma: Phase II trial. Clin Lymphoma 2003;4:36-42.
6. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
7. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. New Engl J Med 2003;348:2690-2691.
8. Swords R, Power D, Fay M, O'Donnell R, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104.
9. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced pulmonary fibrosis. Mayo Clin Proc 2004;79:949-953.
10. Alexandrescu DT, Dutcher JP, O'Boyle K, et al. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004;45:2321-2325.
11. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005;81:169-170.
12. Ghesquieves H. Severe interstitial pneumonitis following rituximab and bleomycin-containing chemotherapy. Ann Oncol 2005;16:1399.
13. Smith M. Rituximab (monoclonal anti-CD20 antibody): Mechanism of action and resistance. Oncogene 2003;22:7359-7368.
14. Van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al. Complement activation plays a key role in the side-effects of rituximab therapy. Br J Haematol 2001;115:807-811.
15. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid tumor clearance. J Clin Oncol 1999;17:791-795.
16. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.
17. Alho HS, Maasitta PK, Harjula AL, et al. Tumor necrosis factor-α in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003;76:516-523.